Since over half of high expressers of whole-cell PAK1 and whole-cell p-PAK1 (Table-S1) were not PAK1-amplified, a larger proportion of PAK1-deregulatd myxofibrosarcomas might harbor non-amplified mechanisms, given that post-transcriptional control, such as non-coding mRNAs or alternative polyadenylation, are increasingly known to operate in various cancers to drive PAK1 expression and/or activation 37, 38. The gene discussed is PAK1; the disease is cancer.